Great Point Partners LLC Has $18.95 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)

Great Point Partners LLC trimmed its position in shares of Evolus, Inc. (NASDAQ:EOLS) by 52.3% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,170,000 shares of the company’s stock after selling 1,281,772 shares during the quarter. Evolus makes up 5.6% of Great Point Partners LLC’s holdings, making the stock its 4th largest holding. Great Point Partners LLC’s holdings in Evolus were worth $18,954,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. California State Teachers Retirement System grew its position in Evolus by 1.6% during the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock valued at $674,000 after buying an additional 739 shares during the period. ProShare Advisors LLC boosted its stake in shares of Evolus by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock worth $162,000 after acquiring an additional 1,035 shares during the last quarter. Essex Investment Management Co. LLC grew its position in shares of Evolus by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock valued at $4,788,000 after acquiring an additional 1,111 shares during the period. Arizona State Retirement System increased its stake in shares of Evolus by 9.4% in the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after purchasing an additional 1,253 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Evolus by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock worth $559,000 after purchasing an additional 1,637 shares during the period. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. The trade was a 6.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This represents a 2.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Evolus Price Performance

NASDAQ:EOLS opened at $12.83 on Wednesday. The business’s 50-day moving average is $15.50 and its 200 day moving average is $13.86. Evolus, Inc. has a 12 month low of $9.29 and a 12 month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Wall Street Analyst Weigh In

Several analysts have issued reports on EOLS shares. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Evolus in a report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Friday, September 13th. Barclays upped their price target on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a report on Monday, September 16th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.